CSPC Pharmaceutical Group (01093.HK): Second Marketing Application for Idaglutide Alpha Injection Accepted by NMPA

NewTimeSpace News: On June 18, 2026, CSPC Pharmaceutical Group (01093.HK) issued a voluntary announcement that the second marketing application for Idaglutide Alpha Injection (trade name: Shanmeining®) developed by its subsidiary has been accepted by the NMPA. The indication submitted this time is glycaemic control in adult patients with type 2 diabetes mellitus, filed as a Class 1 innovative therapeutic biological product.

According to the announcement, the product is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein injection administered once weekly. It stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner to steadily lower blood glucose levels. Meanwhile, it can curb appetite and reduce food intake, delivering weight-regulating effects as an additional benefit.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.